Chimerix, Inc. , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, recently presented data demonstrating CMX001's high barrier to viral resistance in the prevention and treatment of cytomegalovirus infection.
http://www.drugs.com/clinical_trials/chimerix-s-cmx001-resistance-data-presented-26th-international-conference-antiviral-research-15539.html
http://www.drugs.com/clinical_trials/chimerix-s-cmx001-resistance-data-presented-26th-international-conference-antiviral-research-15539.html
No comments:
Post a Comment